Abstract
Background Diabetic Macular Edema (DME) is a complication of diabetes which, when untreated, leads to vision loss. Screening for DME is recommended for diabetic patients every 1-2 years, however compliance rates are low. Though there is currently no high-efficacy camera-agnostic system for DME detection, an AI system may improve compliance.
Methods A deep learning model was trained for DME detection using the EyePacs dataset. Data was randomly assigned, by participant, into development (n= 14,246) and validation (n= 1,583) sets. Analysis was conducted at the single image, eye, and patient levels. Model performance was evaluated using sensitivity, specificity, and AUC.
Findings At the patient level, sensitivity of 0.901 (CI 95% 0.879-0.917), specificity of 0.900 (CI 95% 0.883-0.911), and AUC of 0.962 (CI 95% 0.955-0.968) were achieved. At the image level, sensitivity of 0.889 (CI 95% 0.878-0.900), specificity of 0.889 (CI 95% 0.877-0.900), and AUC of 0.954 (CI 95% 0.949-0.959) were achieved. At the eye level, sensitivity of 0.905 (CI 95% 0.890-0.920), specificity of 0.902 (CI 95% 0.890-0.913), and AUC of 0.964 (CI 95% 0.958-0.969) were achieved.
Interpretation DME can be detected from color fundus imaging with high performance on all analysis metrics. Automatic DME detection may simplify screening, leading to more comprehensive screening for diabetic patients. Further prospective studies are necessary.
Funding Provided by AEYE Health Inc.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding provided by AEYE Health Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Sterling Institutional Review Board reviewed the study and an exemption was obtained
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available online at https://www.eyepacs.com https://www.adcis.net/en/third-party/messidor2/
